Navidea Biopharmaceuticals (NYSE:NAVB) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a report released on Tuesday. The firm set a “sell” rating on the stock.

Navidea Biopharmaceuticals Price Performance

Shares of NYSE:NAVB opened at $0.04 on Tuesday. The company has a market capitalization of $4.00 million, a P/E ratio of -0.67 and a beta of 1.13. Navidea Biopharmaceuticals has a 1-year low of $0.02 and a 1-year high of $0.18. The firm’s 50 day simple moving average is $0.04 and its two-hundred day simple moving average is $0.05.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.